Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Sci. STKE, 13 July 2004
Vol. 2004, Issue 241, p. eg9
[DOI: 10.1126/stke.2412004eg9]

EDITORIAL GUIDES

Focus Issue—Tailoring the Immune Response

Elizabeth M. Adler*

Associate Editor of Science's STKE, American Association for the Advancement of Science, 1200 New York Avenue, N.W., Washington, DC 20005, USA.

Abstract: Recent advances have led to increasing sophistication in our ability to manipulate the immune response to prevent or treat disease. Monoclonal antibodies have emerged as a viable therapeutic approach against both cancer and autoimmune disease. Rituximab, the first monoclonal antibody approved by the FDA for cancer therapy, appears to achieve its therapeutic effects through a combination of mechanisms that may include antibody-dependent cell-mediated cytotoxicity, complement-mediated cell lysis, and the direct stimulation of apoptotic signaling pathways in target cells. Moreover, an increased understanding of the factors that govern immune tolerance has poised us on the brink of further breakthroughs in the immunotherapy of cancer and autoimmune disease. Manipulation of the signaling pathways that lead to T cell anergy may allow us to promote or overcome tolerance as appropriate in the therapy of autimmune disease and cancer. Activation of toll-like receptor pathways in dendritic cells is one approach that may help break tumor tolerance and thereby enhance the efficacy of anti-cancer dendritic cell vaccines.

*Contact information. E-mail, eadler{at}aaas.org

Citation: E. M. Adler, Focus Issue—Tailoring the Immune Response. Sci. STKE 2004, eg9 (2004).

Read the Full Text

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882